Test Price
2,800 AED✅ Home Collection Available
EYA4 Gene (DFNA10) Autosomal Dominant Hearing Loss Genetic Test (NGS) in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO 15189 accredited Next‑Generation Sequencing (Illumina) with comprehensive bioinformatics pipeline.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post‑test result interpretation by a DHA‑licensed Consultant Medical Genetics.
- Insurance Support: Direct billing verification – WhatsApp +971 54 548 8731.
Test Overview & Methodology
The EYA4 Gene Autosomal Dominant Hearing Loss Genetic Test employs Next‑Generation Sequencing to detect pathogenic variants in the EYA4 gene (DFNA10 locus). This test is indicated when clinical audiometry reveals post‑lingual, bilateral sensorineural hearing impairment with a positive family history. It delivers a definitive molecular diagnosis to guide auditory rehabilitation, cochlear implant planning, and family genetic counselling.
| Parameter | Our Test – NGS (Full Gene) | Alternative – Targeted PCR Panel |
|---|---|---|
| Methodology | Next‑Generation Sequencing (Illumina) + bioinformatics pipeline | PCR‑based analysis of known hotspot mutations only |
| Variant Detection | All exons, splice sites – novel & known variants | Limited to pre‑selected point mutations |
| Analytical Sensitivity | >99.9% for single‑nucleotide variants | ~95% for targeted regions |
| Turnaround Time | 3–4 weeks | 4–6 weeks (may require reflex NGS) |
| UAE Regulatory Compliance | DNA Labs UAE – DHA Facility License 1143, accredited under ISO 15189 and DHA quality standards | Often outsourced without direct local quality oversight |
Physician Insight & Safety Protocols
“When a family carries the burden of progressive hearing loss, a precise genetic answer often brings emotional relief and practical direction. I always ensure that my patients understand that this test is a piece of the clinical puzzle, not a standalone verdict, and that a careful, compassionate interpretation makes all the difference.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
Do not discontinue any prescribed hearing aids or medications without consulting your doctor. Discuss your test results with your ENT specialist to adjust treatment safely.
Emergency Red Flags: Seek immediate medical attention if you experience sudden, profound hearing loss with vertigo, facial weakness, or severe tinnitus. Do not rely on genetic testing for acute crises.
Pre‑test Requirements: A mandatory genetic counselling session is required to draw a three‑generation pedigree, explain autosomal dominant inheritance, and obtain documented informed consent per DHA regulations. No dietary or medication adjustments are needed; however, if you are on anticoagulants, please inform the phlebotomist to ensure safe blood draw. Accepted sample types: Whole blood (EDTA), dried blood spot on FTA card, or extracted DNA (shipped at ambient temperature).
Patient Exclusion Criteria
- Individuals unable to provide informed consent or without a legal guardian. Minors must have consent from a guardian per DHA standards.
- Severe, uncontrolled bleeding diathesis; ensure coagulation profile is normal before blood draw.
- Acute psychiatric distress that may compromise understanding of genetic information.
- Pregnancy is not a contraindication; however, post‑partum sample collection is preferred for comfort.
Patient FAQ & Clinical Guidance
1. What is the EYA4 gene test and who should consider it?
This next‑generation sequencing analysis detects pathogenic variants in the EYA4 gene causing autosomal dominant nonsyndromic sensorineural hearing loss. It is recommended for individuals with progressive post‑lingual hearing deterioration and a family history of similar deafness.
2. How long until I receive my results and what is the cost?
Turnaround time is 3 to 4 weeks for the comprehensive NGS report, priced at 2,800 AED inclusive of home blood collection, genetic counselling, and telephonic post‑test result interpretation.
3. Is this genetic test covered by UAE health insurance?
Many UAE insurers approve medically indicated EYA4 testing when accompanied by an ENT or geneticist referral. We provide direct billing verification via secure WhatsApp at +971 54 548 8731.
UAE Regulatory & Data Privacy Adherence
Data Privacy and Security: DNA Labs UAE complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed with strict confidentiality and stored on encrypted servers within the UAE. Patient safety and consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
DHA Facility License: 1143 | Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
Clinical & Logistical Metadata
| Test Name | EYA4 Gene (DFNA10) Autosomal Dominant Hearing Loss Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (EDTA), dried blood spot (FTA card), or extracted DNA |
| Methodology Used | Next‑Generation Sequencing (Illumina) with full bioinformatics analysis |
| ICD-10-CM Code | H90.5 (Unspecified sensorineural hearing loss) |
| LOINC Code | 94513-5 (EYA4 gene targeted mutation analysis) |
| DHA Facility License & Address | DNA Labs UAE | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians